SCHEDULE 13G/A 0000929638-24-001033 0001583977 XXXXXXXX LIVE 4 Common Stock, par value $0.0001 per share 12/11/2025 0001595097 Corbus Pharmaceuticals Holdings, Inc. 21833P301 500 River Ridge Drive Norwood MA 02062 Rule 13d-1(b) Cormorant Asset Management, LP b DE 0 2344971 0 2344971 2344971 N 13.36 IA PN Chen Bihua b X1 0 2344971 0 2344971 2344971 N 13.36 IN HC Corbus Pharmaceuticals Holdings, Inc. 500 River Ridge Drive, Norwood, Massachusetts, 02062 Cormorant Asset Management, LP Bihua Chen 200 Clarendon Street, 52nd Floor Boston, MA 02116 Cormorant Asset Management, LP - Delaware Bihua Chen - United States N IA HC 2,344,971 13.36 0 2,344,971 0 2,344,971 Shares reported herein for Cormorant Asset Management, LP ("Cormorant") represent shares which are beneficially owned by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"). Cormorant Global Healthcare GP, LLC ("GP LLC") serves as the general partner of the Master Fund. Cormorant serves as the investment manager of the Master Fund. Bihua Chen serves as the managing member of GP, LLC and the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein. The percentages reported herein with respect to the Reporting Persons' holdings are calculated based upon a statement in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended on September 30, 2025, as filed with the Securities and Exchange Commission on November 12, 2025, that there were shares of 17,553,037 Common Stock of the Issuer outstanding as of November 7, 2025. Y N See Item 4. In addition, the Master Fund has the right to receive or the power to direct the receipt of dividends or the proceeds from the sale of more than 5% of the Shares. Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. 99.1 Joint Filing Statement, incorporated by reference to the Joint Filing Statement included with the Schedule 13G amendment filed by the Reporting Persons on November 14, 2025. Cormorant Asset Management, LP /s/ Bihua Chen 12/15/2025 Chen Bihua /s/ Bihua Chen 12/15/2025